Related Experiment Video

Updated: Aug 12, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

14.0K

PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response

Arian Ansardamavandi1, Mehrdad Nikfarjam1,2, Hong He1

  • 1Department of Surgery, Austin Precinct, The University of Melbourne, 145 Studley Rd, Heidelberg, VIC 3084, Australia.

Cells
|December 9, 2023
PubMed

Insights

Anti-angiogenesis therapy hinders chemotherapy and survival in pancreatic cancer. Vessel normalization and targeting p21-activated kinases (PAKs) show promise for improving cancer treatment by enhancing immune cell infiltration and drug delivery.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunotherapy

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for solid tumor growth.
  • Anti-angiogenesis drugs, while starving tumors, can impede chemotherapy delivery and fail to improve survival in pancreatic cancer.
  • Vessel normalization emerges as a strategy to improve drug delivery and immune cell infiltration into tumors.

Purpose of the Study:

  • To review the role of p21-activated kinases (PAKs) in tumor vasculature and therapeutic response.
  • To highlight PAK inhibition as a strategy to overcome limitations of anti-angiogenesis therapy.
  • To focus on the implications for pancreatic cancer treatment.

Main Methods:

  • Literature review of current research on PAKs, tumor vasculature, and cancer therapeutics.
  • Analysis of studies investigating PAK inhibition in various cancer models.
  • Synthesis of evidence regarding the impact of PAKs on immune cell infiltration and chemotherapy efficacy.

Main Results:

  • PAK inhibition demonstrates potential in inhibiting cancer cell growth and enhancing chemotherapy efficacy.
  • Inhibition of PAKs promotes anti-tumor immunity and improves the effectiveness of immune checkpoint blockade therapies.
  • Targeting PAKs can reprogram the tumor vascular microenvironment, enhancing CAR-T immunotherapy outcomes.

Conclusions:

  • PAKs play a significant role in regulating tumor vasculature and influencing therapeutic responses.
  • Inhibiting PAKs offers a promising approach to improve anti-cancer treatments, including chemotherapy and immunotherapy.
  • Further research into PAK-targeted therapies is warranted, particularly for challenging cancers like pancreatic cancer.
Keywords:
angiogenesischemotherapyimmunotherapyp21-activated kinases (PAKs)pancreatic cancervessel normalisation

More Related Videos

Author Spotlight: Revolutionizing Pancreatic Disease Understanding Through Advanced Intravital Imaging07:12

Author Spotlight: Revolutionizing Pancreatic Disease Understanding Through Advanced Intravital Imaging

Published on: October 6, 2023

2.0K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

824

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...